Leukeran (Chlorambucil)

Chlorambucil belongs to the alkylating agent class. It attaches alkyl groups to DNA bases, creating cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing malignant lymphocytes.

The dosage of Leukeran is individualized by the prescribing physician based on the patient’s diagnosis, disease stage, body surface area, and laboratory parameters. Only a qualified healthcare professional can determine the appropriate regimen.

Chlorambucil is classified as potentially harmful to a developing fetus and may be excreted in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their oncologist, as the drug is generally avoided in these situations.

To request Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, offering a convenient administration route compared with intravenous regimens such as bendamustine or rituximab‑based combinations. While generally effective for indolent lymphoid malignancies, it may have a different side‑effect profile and is often chosen for patients who prefer oral therapy or have specific contraindications to other agents.

Leukeran should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Leukeran is taken orally, usually with water, and may be administered with or without food depending on the prescriber’s instructions. The exact schedule—daily, weekly, or cyclic—depends on the individual treatment plan set by the oncologist.

The most serious risks include severe bone‑marrow suppression leading to infections or bleeding, secondary malignancies, and rare but life‑threatening reactions such as aplastic anemia or pulmonary fibrosis. Patients should be monitored regularly for blood‑cell counts and any new symptoms.

Leukeran is contraindicated in patients with known hypersensitivity to chlorambucil or other alkylating agents, in those with severe bone‑marrow failure, and in pregnant or breastfeeding women unless the benefits outweigh the risks. Clinicians should also avoid use in patients receiving other highly myelosuppressive therapies without careful monitoring.